It Flopped on Primary Endpoint, But Succeeded on Visual Acuity | ASRS 2023
July 31st 2023AXNOO7, an investigational agent for geographic atrophy, did not affect geographic atrophy lesions but showed positive effects of tests of visual acuity. A novel, neuroprotective mechanism of action may be why.
Read More
When a Biosimilar Might Increase Not Decrease Costs | Ravi Parikh, M.D., M.P.H., ASRS 2023
July 30th 2023The approval of an ophthalmic bevacizumab biosimilar might mean the end of low-cost, repackaged Avastin as an anti-VEGF treatment for retinal diseases, with the unintended consequence of adding $457 million to Medicare B spending.
Read More
The Anti-VEGF Biosimilars Paradox | Ravi Parikh, M.D., M.P.H., ASRS 2023
July 30th 2023In an interview with MHE, Parikh, a retina specialist in New York and director of healthcare delivery research for the Department of Ophthalmology at NYU Grossman School of Medicine, described the current situation of biosimilars in retinal medicine and the attitudes of retinal specialists about using the lower-cost alternatives.
Read More
The Response of New GA Therapies From Patients, Payers | ASRS 2023
July 30th 2023In an interview with MHE, Paul Hahn, M.D., Ph.D., vitreoretinal surgeon at NJRetina, talked about the latest geographic atrophy treatments, pegcetacoplan and avacincaptad pegol, from a coverage and healthcare resource utilization standpoint, as both will potentially be available for the chronic disease that previously had no treatments.
Read More
Effectiveness of Pegcetacoplan, Avacincaptad Pegol in Geographic Atrophy Treatment | ASRS 2023
July 30th 2023Paul Hahn, M.D., Ph.D., vitreoretinal surgeon at NJRetina, chatted with MHE about the latest geographic atrophy treatments and shared key takeaways found from clinical trials examining them. Hahn presented on macular degeneration today at the American Society of Retina Specialists annual meeting in Seattle.
Read More
Endophthalmitis After Anti-VEGF Injections: A Rare But Real Risk | ASRS 2023
July 30th 2023Researchers used the American Academy of Ophthalmology's IRIS database to quantify the risk of endophthalmitis — inflammation of intraocular fluids — after injections with anti-VEGF drugs. They found that post-injection endophthalmitis occurs, on average, once every 3,500 injections.
Read More
Eylea Biosimilar Produces Favorable Results in a Switching Study | ASRS 2023
July 30th 2023Samsung Bioepsis' SB15 was comparable to Eylea (aflibercept) in a 56-week randomized clinical trial that included a rerandomization at 32 weeks. The rerandomization resulted in 111 study volunteers switching from Eylea to the biosimilar for the last part of the study.
Read More
The Long and Short (Interval Switch) of the PULSAR Trial | ASRS 2023
July 29th 2023About 20% of patients in the trial of a high-dose, longer-interval regimen of Eylea (aflibercept )switched to shorter intervals, according to data presented today at the American Society of Retinal Specialists annual scientific meeting, which is being held in Seattle. Researchers didn't find any clues as to why in their baseline characteristics.
Read More
Geographic Atrophy Presents Significant Burden to Patients and Caregivers | ASRS 2023
July 29th 2023Patients with geographic atrophy and their caregivers would benefit from support and accommodations related to managing daily life activities and social activities, as well as their mental health, Sophie J. Bakri, M.D., said during her presentation
Read More
A Primer on PULSAR | Keyvan Koushan, M.D., ASRS 2023
July 29th 2023In an interview with Managed Healthcare Executive prior to the meeting, Keyvan Koushan, M.D., a retina specialist at the Toronto Retina Institute and a lecturer in the Department of Ophthalmology and Vision Sciences at the University of Toronto, briefly described the design of the PULSAR trial and the positive results that have been reported so far.
Read More
Re Syfovre: ‘It’s a Healthy Debate. It’s a Debate We Should Be Having’ | Charles Wykoff, M.D., Ph.D.
July 28th 2023Pros and cons of Syfovre (pegcetacoplan), the newly approved drug for geographic atrophy will be discussed at the American Society of Retinal Specialists annual scientific meeting in Seattle this weekend, predicts leading member of the society. Biosimilars are also on the agenda.
Read More
4 Highlights of the ASRS Annual Scientific meeting | Charles Wykoff, M.D., Ph.D.
July 28th 2023Charles Wykoff, M.D., Ph.D., director of clinical research at Retina Consultants of Texas, noted new treatments for geographic atrophy are predicted to be a hot topic at the American Society of Retina Specialists annual scientific meeting that starts today in Seattle.
Read More